Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Tolerance and Pharmacokinetics With Capecitabine Given 5 Days Out of 7 in Metastatic Breast Cancer

NCT00324610 is registered in ClinicalTrials.gov with Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie as lead sponsor.

NCT NCT00324610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00324610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Tolerance and Pharmacokinetics With Capecitabine Given 5 Days Out of 7 in Metastatic Breast Cancer
Lead sponsor
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2006
Completion date
Not reported
Enrollment
46
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, chemotherapy